Situation: CMS/HHS-related pressure points are converging around value-based payment participation, Medicare Advantage quality economics, Medicaid program integrity, and data liquidity. The sharpest VBC signal is new reporting that Black and Hispanic Medicare beneficiaries remain underrepresented in value-based payment models, raising immediate questions about whether ACOs, MA value contracts, and other APMs are scaling equitably or selectively enrolling easier-to-manage populations (AJMC; Health Equity & SDoH). At the same time, ACHP is pressing CMS to extend the 2026 MA Star Ratings hold-harmless methodology into 2027, a direct bid to stabilize plan revenue and quality bonus exposure as Star methodology volatility continues to affect payer-provider contracts (ACHP; Quality Metrics & Performance).

On the regulatory side, HHS deferred more than $1 billion in Medicaid payments to California and Minnesota pending review of high-risk claims for fraud, signaling a more aggressive program-integrity posture under the Trump administration’s HHS, led by Secretary Robert F. Kennedy Jr. (Open Minds; Policy & Regulatory Changes). Separately, reporting that the Trump administration is demanding hospitals share emergency room records puts interoperability, surveillance, and compliance obligations back on the executive agenda (Fierce; Health IT & Interoperability).

Background: These developments land in a market already moving from “participation in VBC” to enterprise operating model redesign. Endeavor Health’s refusal to silo VBC reflects where sophisticated systems are heading: embedding value strategy into network design, clinical operations, contracting, analytics, and access—not treating it as a payer innovation sidecar (Endeavor; Value-Based Contracting). Risant Health’s platform strategy similarly reinforces that scale in VBC increasingly depends on common infrastructure: data, care model playbooks, physician enablement, and performance management (Risant).

The affordability backdrop is intensifying. Wakely’s Medicare oncology analysis argues that trend is driven not simply by unit price but by adoption, duration, benefit channel, and replacement dynamics, which matters for ACOs, MA plans, and oncology groups taking downside risk (Wakely; Healthcare Affordability). Meanwhile, ASCO’s warning on Medicaid work requirements underscores the operational reality: coverage friction for high-need populations can quickly become avoidable acuity, uncompensated care, and broken care plans (ASCO).

Assessment: The signal is clear: VBC is entering a scrutiny phase. CMS under Administrator Dr. Mehmet Oz, with CMMI Director Abe Sutton, is operating in an environment where value models will be judged not only on savings, but on who gets included, what quality measures pay for, and whether data infrastructure can support real accountability. The AJMC findings on underrepresentation are not a side equity issue; they are a model-validity issue. If VBP models miss Black and Hispanic beneficiaries, then benchmarks, savings claims, and quality narratives are incomplete.

MA plans’ push for Star Ratings hold-harmless protection shows the other side of the same coin: quality measurement instability directly affects capital allocation, provider incentives, and contract appetite. Plans and providers cannot underwrite multiyear risk if measure mechanics swing faster than operations can adapt. Yet permanent insulation from Star pressure would weaken accountability. The right executive posture is not to wait for CMS relief—it is to stress-test contracts against multiple Star and coding scenarios now.

Program-integrity actions in Medicaid and ER data-sharing demands also point to a Trump administration bias toward auditability, data access, and fraud control. That creates risk for organizations with fragmented records, loose delegated-vendor oversight, or weak claims provenance. It creates advantage for enterprises that can prove medical necessity, close documentation gaps, and surface utilization patterns in near real time.